Collectively, our findings on clinical tissues from HCC were highly consistent with the molecular and cellular biology results, further supporting the hypothesis that HSP90β impedes STUB1‐induced ubiquitination of YTHDF2 to drive the growth and sorafenib‐insensitivity of HCC (Figure 8G). Here, HSP90AB1 is linked to hepatocellular carcinoma.